Publications by authors named "Ian Keyzor"

Claim this Profile
A
A multi-country time and motion study to describe the experience and burden associated with the treatment of Fabry disease with enzyme replacement therapy with agalsidase alfa and agalsidase beta.
Ian Keyzor, Ana Maria Martins, Sema Kalkan Uçar, Hiroyuki Yamakawa, Yin-Hsiu Chien

Orphanet J Rare Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data.
Simon Shohet, Noemi Hummel, Shuai Fu, Ian Keyzor, Alasdair MacCulloch

J Comp Eff Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease.
Kristl G Claeys, Hani Kushlaf, Syed Raza, Noemi Hummel, Simon Shohet, Ian Keyzor

Orphanet J Rare Dis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS) physical function questionnaire in late-onset Pompe disease using PROPEL phase 3 data.
Priya S Kishnani, Simon Shohet, Syed Raza, Noemi Hummel, Jeffrey P Castelli, Ian Keyzor

J Patient Rep Outcomes· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification.
Ian Keyzor, Simon Shohet, Jeff Castelli, Sheela Sitaraman, Biliana Veleva-Rotse

Biomolecules· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Selective Laser Trabeculoplasty in the United Kingdom.
Anthony P Khawaja, Joanna H Campbell, Nicholas Kirby, Hitesh S Chandwani, Ian Keyzor

Ophthalmology· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK.
Georgia Hollier-Hann, Alistair Curry, Kateryna Onishchenko, Ron Akehurst, Fayyaz Ahmed, Ian Keyzor

J Med Econ· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.
David Price, Yumi Asukai, Jaithri Ananthapavan, Bill Malcolm, Amr Radwan, Ian Keyzor

Appl Health Econ Health Policy· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis